In this issue of Blood , Casasnovas et al demonstrate that among diffuse large B-cell (DLBCL) patients with age-adjusted International Prognostic Index (aaIPI) 2-3, the dose-dense immunochemotherapy (IC) regimen rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (R-ACVBP) was no better than rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP14). Using an interim positron emission tomography (PET)–adapted approach to consolidation therapy, they show that quantitative rather than qualitative PET assessment may better select some patients needing alternative treatments, including autologous stem cell transplantation (ASCT). 1

中文翻译：

---

高危 DLBCL：临时 PET？还没有

在本期血液中，Casasnovas 等人证明，在年龄调整国际预后指数 (aaIPI) 2-3 的弥漫性大 B 细胞 (DLBCL) 患者中，剂量密集免疫化疗 (IC) 方案利妥昔单抗、多柔比星、环磷酰胺、长春地辛、博来霉素、泼尼松 (R-ACVBP) 并不比利妥昔单抗、环磷酰胺、多柔比星、长春新碱、泼尼松 (R-CHOP14) 好。使用临时正电子发射断层扫描 (PET) 适应的巩固治疗方法，他们表明定量而非定性 PET 评估可能更好地选择一些需要替代治疗的患者，包括自体干细胞移植 (ASCT)。1